Mankind Pharma has partnered with BDR Pharmaceuticals for distributing the anti-COVID19 drug Baricitinib under the trademark Barikind that received restricted emergency use approval for use in combination with remdesivir, a company statement said.
According to the statement, under the partnership, BDR Pharma will be manufacturing and marketing the product under a royalty-free, limited and non-exclusive voluntary licence from Eli Lilly and Company, and Mankind Pharma will be distributing the same.
“Baricitinib received restricted emergency use approval for use in combination with remdesivir, for treatment of COVID-19 in hospitalised adults, requiring supplemental oxygen, invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO). Lilly received permission for restricted emergency use from the Central Drugs Standard Control Organisation (CDSCO),” added the statement.